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Background: Patient-specific dose verification for treatment planning in helical tomotherapy is routinely performed
using a homogeneous virtual water cylindrical phantom of 30 cm diameter and 18 cm length (Cheese phantom).
Because of this small length, treatment with total marrow irradiation (TMI) requires multiple deliveries of the dose
verification procedures to cover a wide range of the target volumes, which significantly prolongs the dose
verification process. We propose a fast, simple, and informative patient-specific dose verification method which
reduce dose verification time for TMI with helical tomotherapy.
Methods: We constructed a two-step solid water slab phantom (length 110 cm, height 8 cm, and two-step width
of 30 cm and 15 cm), termed the Whole Body Phantom (WB phantom). Three ionization chambers and three EDR-2
films can be inserted to cover extended field TMI treatment delivery. Three TMI treatment plans were conducted
with a TomoTherapy HiArt Planning Station and verified using the WB phantom with ion chambers and films. Three
regions simulating the head and neck, thorax, and pelvis were covered in a single treatment delivery. The results
were compared to those with the cheese phantom supplied by Accuray, Inc. following three treatment deliveries to
cover the body from head to pelvis.
Results: Use of the WB phantom provided point doses or dose distributions from head and neck to femur in a
single treatment delivery of TMI. Patient-specific dose verification with the WB phantom was 62% faster than with
the cheese phantom. The average pass rate in gamma analysis with the criteria of a 3-mm distance-to-agreement
and 3% dose differences was 94% ± 2% for the three TMI treatment plans. The differences in pass rates between
the WB and cheese phantoms at the upper thorax to abdomen regions were within 2%. The calculated dose
agreed with the measured dose within 3% for all points in all five cases in both the WB and cheese phantoms.
Conclusions: Our dose verification method with the WB phantom provides simple and rapid quality assurance
without limiting dose verification information in total marrow irradiation with helical tomotherapy.Background
Helical tomotherapy offers a high intensity modulated beam
with multileaf collimator while translating the couch into
the gantry [1,2]. This allows the delivery of an intensity
modulated beam for the treatment of very long targets,
such as in total body irradiation (TBI) and total marrow ir-
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distribution, and reproduction in any mediumTo check the accuracy of dose calculations and mechan-
ical issues radiation therapy treatment planning, each in-
tensity modulated treatment plan requires dose verification
before the treatment delivery to the patient. Currently,
each individual plan is calculated in a phantom geometry
and delivered to the phantom. The dose is then measured
with ion chambers and radiographic or radiochromic
films, or with detector arrays alone [12,13]. The calculated
dose is then compared with the measured dose. This pro-
cedure is called delivery quality assurance (DQA). Most
users currently perform DQA using the cylindrical Virtual
Water™ solid water phantom, which was designed and
provide by Accuray, Inc with a 30 cm diameter and 18 cmentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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bers and a radiographic or a GafChromic film in the cor-
onal or sagittal plane.
Unlike treatment of solid tumors, including head and
neck, lung, and prostate cancers, the treatment length
and time of TBI or TMI are markedly long, at more than
90 cm and 30 minutes, respectively [5-7,9]. The com-
plexities are compounded as there are many organs at
risk including the brain, lung, liver, kidneys, and peritoneal
cavity as well as targets (marrow) throughout the whole
body in TMI. In addition, a number of tomotherapy ma-
chines still do not have a dose servo system. These ma-
chines show output fluctuation [13-17], particularly in long
treatment deliveries, corresponding with the later part of
the treatment site (i.e., pelvis and femur) in TMI. These
facts highlight the importance of dose verification for a
wide range of targets where there are critical organs around
to assure the safety of TMI patients. Since the cheese phan-
tom is only 18 cm long, single delivery of DQA in TMI
covers only a small portion of the target. Complete verifica-
tion from the head to femur regions requires repeating the
DQA procedure at least three times for an adult TMI case,
leading to a significant increase in DQA time.
Another possible method of verifying dose distribution
is to use 2D or 3D detector arrays. Although these have
dramatically sped up IMRT dose verification, commer-
cially available arrays are not suitable in TMI because of
their limited array size, which requires multiple DQA
delivery. Furthermore, the electronic circuit of a 2D or 3D
array will be irradiated in TMI delivery, resulting in dam-
age to the detector array. The only way to verify the dose
and dose distribution in such situations is to use film.
Here, we propose a simple, fast and informative DQA
method for TMI delivery with film.
Methods
1. Set up of the cheese phantom, ion chambers and films.
The cheese phantom made of Virtual water™ is a
cylindrical phantom of 15 cm radius and 18 cm
length which is cut into two semi cylindrical halves
where a sheet of film can lie along the central axis of
the phantom (Figure 1 (a)). The phantom also has a
series of holes to allow for the insertion of an
Exradin A1SL ion chamber with the volume of
0.053 cc (A1SL, Standard imaging, WI, USA). In the
present study, an ion chamber and an EDR2 film
with 30.5 cm length and 25.4 cm width (Kodak,
Nagano, Japan) in the coronal plane were placed as
shown in Figure 1 (a).2. Set up of the WB phantom, ion chambers and films
Using similar materials as the cheese phantom, we
built a two-step solid water slab phantom as seen inFigures 1 (b) and (c). This Whole Body Phantom
(WB phantom) offers a total length of 110 cm, 8 cm
height and two step widths of 30 cm and 15 cm.
Three EDR2 films that cover approximately 90 cm
can be inserted into this phantom (Figure 1 (b)) as
well as three A1SL ionization chambers. Point doses
can then be measured at locations corresponding to
the upper humerus (Chamber 1 in Figure 1 (d)),
thoracic vertebrae (Chamber 2 in Figure 1 (d)), and
pelvic bones (Chamber 3 in Figures 1 (e) and (f )).3. Treatment planning
TMI treatment planning for five patients was
conducted with the TomoTherapy HiArt Planning
Station (Accuray, Inc., Madison, WI). Target and
avoidance structures including brain, lenses, eyes,
parotid glands, thyroids, lungs, heart, kidneys, liver,
peritoneum, bladder, and rectum were contoured on
a Pinnacle treatment planning system (Philips
Medical Systems, Palo Alto, CA). The planning
target volume (PTV) was generated by adding
margins of 5 mm to thoracic bones, 1.5 cm to femur
and shoulder bones, and 1 cm to all other bones.
The DICOM-RT structure set was then transferred
to the TomoTherapy HiArt Planning Station.
A prescription of 18 Gy/3 fractions was used for
planning simulation to cover 85% of PTV with the
prescription dose. The pitch, modulation factor and
Jaw size were 0.200 or 0.287, 2.5, and 5 cm,
respectively. Final dose calculation was performed
with the convolution/superposition algorithm with
the calculation grid size of 0.391 cm.4. Delivery QA and the verification analysis
Kilovoltage CT images of the cheese and WB
phantoms were taken with the same technique as the
TMI patient scans. Five TMI treatment plans were
transferred to the tomotherapy DQA workstation.
For DQAs with the cheese phantom, three DQA
procedures per patient were created in the Tomo
DQA workstation. The cheese phantom was moved
three times so that the phantom covered locations
corresponding to the head and neck, thorax, or
pelvis. The doses were then recalculated in the
phantom by using the sinogram from the original
TMI planning in human body. This recalculation
was based on the image value-to-density calibration
(IVDC) table consisting of 13 different density plugs
which was also used for the patient dose calculation.
These three DQA treatment procedures were delivered
to the cheese phantom as a conventional method.
For DQAs with the WB phantom, a single DQA
procedure per patient was created in the Tomo


















Figure 1 Scheme of DQA in TMI planning. (a) Scheme of DQA with the cheese phantom (b) Film alignment in the WB phantom, (c) ion
chamber alignment in the WB phantom. The WB phantom was moved so that the three ion chambers were located at approximately (d) the
upper humerus, (e) thoracic vertebrae and (f) pelvic bone in the dose verification, representing locations where bone marrow is abundant. These
regions are also suitable for point dose measurement because of a high dose and low dose gradient.
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approximately the upper humerus (Figure 1 (d)),
thoracic vertebrae (Figure 1 (d)), and pelvic bone
(Figures 1 (e), and (f )); representing locations where
bone marrow is abundant. These regions are also
suitable for point dose measurement because of a
high dose and low dose gradient. The three films
were placed at the regions of the head and neck to
upper thorax, lower thorax to abdomen, and pelvis
to femur to include the critical organs such as the
brain, lung, kidney, and liver as well as the PTV.
The dose was recalculated in the phantom by using
the sinogram of the original TMI planning of the
human body as shown Figures 1 (d), (e), and (f ).
The DQA procedure was then delivered to the WB
phantom and point doses and planer dose
distributions were measured by the ionization
chambers and EDR-2 films, respectively. The main
difference between DQA deliveries with the cheese
phantom and those with the WB phantom was the
DQA delivery time, namely three deliveries versus a
single delivery.
To analyze differences between measured and
calculated doses, the delivered dose distributions
need to be registered relative to the phantom. To do
that, four points were identified using the fixed cross
laser (green laser). Green cross lasers were marked
on the film at a thorax-to-abdomen site. For headand neck and pelvic regions, we identified the points
at a well-defined distance (e.g.; 20 cm or 25 cm)
from the green laser by using a ruler with the aid of
the tomotherapy couch coordinate readout.
After irradiation, EDR2 films were developed and
scanned using a VIDAR VXR-16 Dosimetry Pro
Scanner (VIDAR Systems Corporation, Herndon, VA,
USA). The EDR2 film analysis was performed in the
DQA workstation. Although Yeo et al. reported that
EDR2 film exhibits considerable energy dependence
(a maximum discrepancy of 9%, compared with an
ion chamber) at 10 cm depth for IMRT field [18],
several reports demonstrated EDR2 film could be used
for absolute dose measurement with ≤3% uncertainty
[19,20]. However, we analyzed the EDR2 films for the
relative dose as already published here [13,21-23] to
avoid the uncertainty from a film developer. The
comparison of longitudinal profiles and gamma
analyses with the criteria of 3 mm/3% between
planned and measured dose was performed. In the
present study, the dose difference criteria in gamma
analysis were defined in respect to the prescribed dose.5. Statistical analysis
The dosimetric results with films and ion chambers
between the cheese phantom and the WB phantom
as well as the differences in time required in each
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(IBM, New York, NY).Results and discussion
Dose verification is an essential part of IMRT clinical prac-
tice. The many organs at risk throughout the whole body
and output fluctuation in long beam-on time demand a
wide range of dose verifications particularly from head to
pelvis where there are critical organs around to ensure pa-
tient safety. Currently, most clinics use the cheese phantom
for DQA in tomotherapy planning. Since the longitudinal
size of this phantom is only 18 cm, the TMI DQA pro-
cedure must be repeated at least three times to verify
the dose for the head and neck, thoracic and pelvic re-
gions in adult patients, which significantly prolongs the
dose verification process.
Here, we developed a simple, fast and informative DQA
method in helical tomotherapy for extremely long target
treatments. The WB phantom provided point doses and
dose distributions from head and neck to femur in a single
TMI treatment delivery.
Table 1 shows the average time required in each
process in the DQA procedure for five TMI cases in our
proposed method (WB phantom) and the standard
method (cheese phantom). Our method reduced DQA
time by 12 minutes (p < 0.0001), 6 minutes (p < 0.0001),
and 76 minutes (p < 0.0001) in the DQA setup, phantom
setup and beam delivery, respectively. This decrease is
because our method requires only a single delivery to
obtain dose distributions from head to pelvis, thus redu-
cing time throughout the entire DQA process.
Figure 2 shows a representative dose verification case
using the WB phantom with EDR2 films. Good agree-
ment of calculated and measured doses was found at the
neck to upper thorax regions (Figures 2 (a), (d)), lower
thorax to abdomen regions (Figures 2 (b), (e)), and pel-
vic to femur regions (Figures 2 (c), (f )). The pass rates in
gamma analysis with a 3 mm distance-to-agreement and
3% dose differences were 96.8% ± 2.1%, 93.6% ± 0.5%, and
91.6% ± 0.2% for the regions of head and neck–upper
thorax, lower thorax-abdomen, and pelvis-femur, respect-
ively (Table 2). Moreover, our results showed that our
DQA method could cover the dose distribution from heade 1 Time required in each process in the DQA






setup in the DQA
station
10.4 ± 1.5 22.2 ± 0.8 p < 0.0001
om setup 9.2 ± 1.3 15.0 ± 1.0 p < 0.0001
delivery 37.8 ± 2.3 113.4 ± 6.9 p < 0.0001
57.4 ± 2.3 150.6 ± 6.1 p < 0.0001and neck to femur with the single delivery of a TMI QA
procedure.
Since use of the cheese phantom is the standard method
for DQA, we conducted DQA procedures for three ana-
tomical regions in five TMI treatment plans using both
the WB and cheese phantoms. Table 2 compares pass
rates in gamma analysis with the same acceptance criteria
for the five TMI cases between the two phantoms. The
differences in pass rate between cheese phantom and WB
phantom were within 3% with no statistical significance
for five TMI cases. The worst pass rate was 90% at the
pelvic-femur region with both phantoms, but this is con-
sidered acceptable according to the report of AAPM task
group 148 [13].
Table 3 shows the results of point dose verification
with ion chambers for the five TMI cases. The calculated
dose agreed with the measured dose within 3% for all
points in all five cases with both the WB and cheese
phantom. These results indicate that the WB phantom
provides closely similar results to the cheese phantom.
Dose verification for TBI or TMI with helical tomother-
apy has been performed with various phantoms and detec-
tors. Gruen et al. performed dose verification using a
cheese phantom for point dose measurement with ion
chambers [4]. Zhuang et al. used a Meditec solid water
phantom of 30 cm (length) × 30 cm (width) × 12 cm
(depth) with a 0.6 cc PTV farmer-type ion chamber and
EDR2 film [24]. Hui et al. used a cylindrical phantom of
30 cm diameter and 36 cm length [7]. None of these are
long enough to verify the large treatment lengths used in
TBI or TMI. In addition, use of a 0.6 cc ion chamber is
not always appropriate in verification of high intensity
modulated plans because of the large size of the ion cham-
ber. Several groups have used TLDs in a rando phantom
to verify doses for TMI or TBI, [4,6,25]; this allows meas-
urement of point doses in the whole body in a single deliv-
ery of a TMI treatment plan. In our method, one delivery
of the DQA procedure enables the measurement of both
point doses using smaller ion chambers (0.053 cc com-
pared to 0.6 cc farmer type ion chamber) and dose distri-
butions from the head and neck to pelvis, which offers
more informative QA results.
The advantages of our DQA method are not only a re-
duction in DQA time and coverage of dose distribution
from the head and neck to femur, but also a decrease in
cost, since it uses a vendor-supplied phantom and the
detectors present in a tomotherapy machine.
The number of clinics providing TBI or TMI with hel-
ical tomotherapy in the past few years has increased
[3,5,7-11,24]. Dosimetric studies on volumetric arc ther-
apy for TBI or TMI with conventional linear accelerators
have also been extensively performed [25-28]. These stud-
ies used an electric portal imaging system, or 2D or 3D





























Figure 2 Comparison of dose distributions in TMI planning between calculated and measured doses by three EDR-2 films in the WB
phantom. (a) The isodose lines were overlaid at (a) head and neck to upper thorax region, (b) lower thorax to abdominal region, and (c) pelvic
bone to femur region, (d) gamma distribution in the region shown in (a), (e) gamma distribution in the region shown in (b), (f) a gamma distribution
in the region shown in (c). Note that gamma value outside the phantom as shown in figure (e) was not included to calculate the pass rate.
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mercially available 2D and 3D arrays still require multiple
treatment delivery in TMI DQA because of the limitation
in array size, which significantly prolong the DQA process.
Development of a detector array suitable for long treatment
deliveries such as TMI would be useful. In the presentTable 2 Percentage of points passing gamma criteria of
3%/3mm in DQA with EDR2 films for five TMI cases
Region WB phantom Cheese phantom P-value
(%) (%)
Head and neck to
upper thorax
96.8 ± 2.1 95.2 ± 3.1 0.421
Lower thorax to abdomen 93.6 ± 0.5 94.1 ± 2.4 0.548
Pelvis to femur 91.6 ± 0.2 93.5 ± 3.0 0.222study, we used EDR2 film to verify 2D dose distribution.
Although many clinics have decommissioned their radio-
graphic film developer, EDR2 film has been commonly
used in many clinics [17,19-23,29-32]. Currently, an in-
creasing number of clinic use GafChromic films, which do
not require a film developer for IMRT QA. Our methodTable 3 Agreement of calculated dose with ion chamber
measurements in% for five TMI cases
Region WB phantom Cheese phantom P-value
(%) (%)
Head and neck to
upper thorax
−0.14 ± 1.44 1.36 ± 1.19 0.151
Lower thorax to abdomen 0.26 ± 1.8 0.97 ± 1.41 0.548
Pelvis to femur 0.31 ± 2.52 0.41 ± 1.39 0.222
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EDR2 film.
In addition to its use in tomotherapy, our method is
also applicable to long treatments such as TBI, total skin
irradiation, and cranial-spinal irradiation with volumetric
arc therapy in a conventional linear accelerator, particu-
larly to verify the dose in the field junction.
Conclusions
Our DQA method with WB phantom could provide a
fast, accurate, simple and informative procedure for total
marrow irradiation with helical tomotherapy. This tech-
nique might offer rapid quality assurance without limit-
ing dose verification information.
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